Role of hepatitis C virus substitutions and interleukin-28B polymorphism on response to peginterferon plus ribavirin in a prospective study of response-guided therapy

Journal of Viral Hepatitis

Volumn 20, Issue 11, 2013, Pages 761-769

  Liang, C M ^a   Hu, T H ^a   Lu, S N ^a   Hung, C H ^a   Huang, C M ^a   Wang, J H ^a   Yen, Y H ^a   Chen, C H ^a   Chang, K C ^a   Tsai, M C ^a   Kuo, Y H ^a   Lee, C M ^a  

^a CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

Author keywords

core protein; hepatitis C virus; interferon sensitivity determining region; interleukin 28B; sustained virological response

Indexed keywords

ALPHA2B INTERFERON PLUS RIBAVIRIN; ARGININE; INTERLEUKIN 28B; LEUCINE; RIBAVIRIN;

ADULT; AMINO ACID SUBSTITUTION; ARTICLE; DNA POLYMORPHISM; FEMALE; GENE MUTATION; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; MAJOR CLINICAL STUDY; MALE; PREDICTIVE VALUE; PREMEDICATION; PRIORITY JOURNAL; PROSPECTIVE STUDY; THROMBOCYTE COUNT; TREATMENT DURATION; TREATMENT RESPONSE; VIRUS LOAD;

CORE PROTEIN; HEPATITIS C VIRUS; INTERFERON SENSITIVITY-DETERMINING REGION; INTERLEUKIN-28B; SUSTAINED VIROLOGICAL RESPONSE;

AGED; ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; FEMALE; GENOTYPE; HEPATITIS C, CHRONIC; HUMANS; INTERFERONS; INTERLEUKINS; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROSPECTIVE STUDIES; RIBAVIRIN; TREATMENT OUTCOME; VIRAL LOAD; VIRAL NONSTRUCTURAL PROTEINS;

EID: 84885483011     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/jvh.12097     Document Type: Article

References (40)

1. Niederau C, Lange S, Heintges T, et al,. Prognosis of chronic hepatitis C: results of a large, prospective cohort study. Hepatology 1998; 28: 1687-1695. (Pubitemid 28549142)
2. Ikeda K, Saitoh S, Suzuki Y, et al,. Disease progression and hepatocellular carcinogenesis in patients with chronic viral hepatitis: a prospective observation of 2215 patients. J Hepatol 1998; 28: 930-938. (Pubitemid 28275969)
3. Fried MW, Shiffman ML, Reddy KR, et al,. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975-982.
4. Manns MP, McHutchison JG, Gordon SC, et al,. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomized trial. Lancet 2001; 358: 958-965. (Pubitemid 32913521)
5. McHutchison JG, Lawitz EJ, Shiffman ML, et al,. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med 2009; 361: 580-593.
6. Muir AJ, Bornstein JD, Killenberg PG, Atlantic Coast Hepatitis Treatment Group. Peginterferon alfa 2b and ribavirin for the treatment of chronic hepatitis C in blacks and non-Hispanic whites. N Engl J Med 2004; 350: 2265-2271. (Pubitemid 38669209)
7. Bruno S, Camma C, Di Marco V, et al,. Peginterferon alfa-2b plus ribavirin for native patients with genotype 1 chronic hepatitis C: a randomized controlled trial. J Hepatol 2004; 41: 474-481. (Pubitemid 39158756)
8. Walsh MJ, Jonsson JR, Richardson MM, et al,. Non-response to antiviral therapy is associated with obesity and increased hepatic expression of suppressor of cytokine signaling 3 in patients with chronic hepatitis C, viral genotype 1. Gut 2006; 55: 604-609.
9. Asselah T, Rubbia-Brandt L, Marcellin M, et al,. Steatosis in chronic hepatitis C: why does it really matter? Gut 2006; 55: 123-130. (Pubitemid 41820647)
10. Romero-Gomez M, Del Mar Viloria M, Andrade RJ, et al,. Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients. Gastroenterology 2005; 128: 636-641. (Pubitemid 40585366)
11. Ferenci P,. Predictors of response to therapy for chronic hepatitis C. Semin Liver Dis 2004; 24: 25-S31.
12. Zeuzem S, Hultcrantz R, Bourliere M, et al,. Peginterferon alfa-2b plus ribavirin for treatment of chronic hepatitis C in previously untreated patients infected with HCV genotypes 2 or 3. J Hepatol 2004; 40: 993-999. (Pubitemid 38670134)
13. Ge D, Fellay J, Thompson AJ, et al,. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009; 461: 399-401.
14. Akuta N, Suzuki F, Sezaki H, et al,. Association of amino acid substitution pattern in core protein of hepatitis C virus genotype 1b high viral load and nonvirological response in interferon-ribavirin combination therapy. Intervirology 2005; 48: 372-380. (Pubitemid 41003622)
15. Akuta N, Suzuki F, Kawamura Y, et al,. Predictors of viral kinetics to peginterferon plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus genotype 1b. J Med Virol 2007; 79: 1686-1695. (Pubitemid 47479887)
16. Hayashi K, Katano Y, Ishigami M, et al,. Mutations in the core and NS5A region of hepatitis C virus genotype 1b and correlation with response to pegylated- interferon-alpha 2b and ribavirin combination therapy. J Viral Hepat 2011; 18: 280-286.
17. Enomoto N, Maekawa S,. HCV genetic elements determining the early response to peginterferon and ribavirin therapy. Intervirology 2010; 53: 66-69.
18. Yen YH, Hung CH, Hu TH, et al,. Mutations in the interferon sensitivity- determining region (nonstructural 5A amino acid 2209-2248) in patients with hepatitis C-1b infection and correlating response to combined therapy of pegylated interferon and ribavirin. Aliment Pharmacol Ther 2008; 27: 72-79.
19. Hung CH, Lee CM, Lu SN, et al,. Mutations in the NS5A and E2-PePHD region of hepatitis C virus type 1b and correlation with the response to combination therapy with interferon and ribavirin. J Viral Hepat 2003; 10: 87-94.
20. Hung CH, Lu SN, Wang JH, et al,. Correlation between ultrasonographic and pathologic diagnoses of hepatitis B and C virus-related cirrhosis. J Gastroenterol 2003; 38: 153-157.
21. Wai CT, Greenson JK, Fontana RJ, et al,. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology 2003; 38: 518-526. (Pubitemid 36919874)
22. Ghany MG, Nelson DR, Strader DB, Thomas DL, Seeff LB,. An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology 2011; 54: 1433-1444.
23. Pawlotsky JM,. New Antiviral Agents for Hepatitis C. F1000 Biol Rep 2012; 4: 5.
24. Kurbanov F, Tanaka Y, Matsuura K, et al,. Positive selection of core 70Q variant genotype 1b hepatitis C virus strains induced by pegylated interferon and ribavirin. J Infect Dis 2010; 201: 1663-1671.
25. Hayes CN, Kobayashi M, Akuta N, et al,. HCV substitutions and IL28B polymorphisms on outcome of peg-interferon plus ribavirin combination therapy. Gut 2011; 60: 261-267.
26. Watanabe K, Yoshioka K, Yano M, et al,. Mutations in the nonstructural region 5B of hepatitis C virus genotype 1b: their relation to viral load, response to interferon, and the nonstructural region 5A. J Med Virol 2005; 75: 504-512. (Pubitemid 40293517)
27. Katano Y, Hayashi K, Ishigami M, et al,. Association with 5′-untranslated region and response to interferon in chronic hepatitis C. Hepatogastroenterology 2007; 54: 854-857. (Pubitemid 46903739)
28. Muñoz de Rueda P, Casado J, Patõn R, et al,. Mutations in E2-PePHD, NS5A-PKRBD, NS5A-ISDR, and NS5A-V3 of hepatitis C virus genotype 1 and their relationships to pegylated interferon-ribavirin treatment responses. J Virol 2008; 82: 6644-6653. (Pubitemid 351875141)
29. Sanjo M, Saito T, Ishii R, et al,. Secondary structure of the amino-terminal region of HCV NS3 and virological response to pegylated interferon plus ribavirin therapy for chronic hepatitis C. J Med Virol 2010; 82: 1364-1370.
30. Akuta N, Suzuki F, Hirakawa M, et al,. Amino acid substitution in HCV core/NS5A region and genetic variation near IL28B gene affect treatment efficacy to interferon plus ribavirin combination therapy. Intervirology 2012; 55: 231-241.
31. Macdonald A, Harris M,. Hepatitis C virus NS5A: tales of a promiscuous protein. J Gen Virol 2004; 85: 2485-2502. (Pubitemid 39214345)
32. Gale MJ Jr, Korth MJ, Tang NM, et al,. Evidence that hepatitis C virus resistance to interferon is mediated through repression of the PKR protein kinase by the nonstructural 5A protein. Virology 1997; 230: 217-227. (Pubitemid 27211852)
33. Bode JG, Ludwig S, Ehrhardt C, et al,. IFN-alpha antagonistic activity of HCV core protein involves induction of suppressor of cytokine signaling-3. FASEB J 2003; 17: 488-490.
34. De Lucas S, Bartolome J, Carreno V,. Hepatitis C virus core protein down-regulates transcription of interferon-induced antiviral genes. J Infect Dis 2005; 191: 93-99. (Pubitemid 40041406)
35. Berg T, Weich V, Teuber G, et al,. Individualized treatment strategy according to early viral kinetics in hepatitis C virus type 1-infected patients. Hepatology 2009; 50: 369-377.
36. Ferenci P, Laferl H, Scherzer TM, et al,. Peginterferon alfa-2a and ribavirin for 24 weeks in hepatitis C type 1 and 4 patients with rapid virological response. Gastroenterology 2008; 135: 451-458.
37. Yu ML, Dai CY, Huang JF, et al,. Rapid virological response and treatment duration for chronic hepatitis C genotype 1 patients: a randomized trial. Hepatology 2008; 47: 1884-1893.
38. Huang CF, Yeh ML, Huang JF, et al,. Host interleukin-28B genetic variants versus viral kinetics in determining responses to standard-of-care for Asians with hepatitis C genotype 1. Antiviral Res 2012; 93: 239-244.
39. Craxi A,. EASL clinical practice guidelines: management of hepatitis C virus infection. J Hepatol 2011; 55: 245-264.
40. Lin ZH, Xin YN, Dong QJ, et al,. Performance of the aspartate aminotransferase-to-platelet ratio index for the staging of hepatitis C-related fibrosis: an updated meta-analysis. Hepatology 2011; 53: 726-736.